• Journal of Pharmacopuncture
• /
• v.13 no.4
• /
• pp.43-61
• /
• 2010

Objectives : This study was performed to analyse single dose toxicity of Sweet Bee Venom(Sweet BV) extracted from the bee venom in Beagle dogs. Methods : All experiments were conducted under the regulations of Good Laboratory Practice (GLP) at Biotoxtech Company, a non-clinical study authorized institution. Male and female Beagle dogs of 5-6 months old were chosen for the pilot study of single dose toxicity of Sweet BV which was administered at the level of 9.0 mg/kg body weight which is 1300 times higher than the clinical application dosage as the high dosage, followed by 3.0 and 1.0 mg/kg as midium and low dosage, respectively. Equal amount of excipient(normal saline) to the Sweet BV experiment groups was administered as the control group. Results : 1. No mortality was witnessed in all of the experiment groups. 2. Hyperemia and movement disorder were observed around the area of administration in all the experiment groups, and higher occurrence in the higher dosage treatment. 3. For weight measurement, Neither male nor female groups showed significant changes. 4. To verify abnormalities of organs and tissues, thigh muscle which treated with Sweet BV, brain, liver, lung, kidney, and spinal cords were removed and histologocal observation using H-E staining was conducted. In the histologocal observation of thigh muscle, cell infiltration, inflammation, degeneration, necrosis of muscle fiber, and fibrosis were found in both thigh tissue. And the changes depend on the dose of Sweet BV. But the other organs did not showed in any abnormality. 5. The maximum dose of Sweet BV in Beagle dogs were over 9 mg/kg in this study. Conclusions : The above findings of this study suggest that Sweet BV is a relatively safe treatment medium. Further studies on the toxicity of Sweet BV should be conducted to yield more concrete evidences.

• Journal of Veterinary Clinics
• /
• v.25 no.5
• /
• pp.379-384
• /
• 2008

The objective of this study was to determine output power for skin incision in 0.3 mm spot diameter $CO_2$ laser by measuring (1) the wound depth, (2) initial dermal tissue damage, (3) degree of wound healing at different power (4W, 5W and 6W) in beagle dogs. Three healthy 2-year-old beagle dogs were used. Four 2 cm straight skin incisions were made with 0.3 mm spot diameter $CO_2$ laser on the each dog's both side of dorsal midline in three beagle dogs. The skin incisions were performed for $10{\sim}15$ seconds for same dosage. And then each wound was closed with surgical stapler. At 0, 3, 7 and 14 days after initial wounding, each wound was taken for histological observation. On macroscopic and microscopic observation, initial incisional wound did not show difference in three group. And also re-epithelialization, dermal tissue damage and inflammatory response did not show significant difference among groups. This study reveals that 4W, 5W and 6W may be suitable output power in 0.3 mm spot diameter $CO_2$ laser for the skin incision in beagle dogs.

• Journal of Veterinary Clinics
• /
• v.35 no.3
• /
• pp.77-82
• /
• 2018

The aim of this study was to measure whole blood viscosity (WBV) and then to establish its reference values and identify correlation between WBV and hematology or serum chemistry in beagle. The experiment was made up of 82 healthy beagle dogs. Jugular vein blood samples (10 ml) were collected. WBV (cP) measured within 4 hours after collection by U-shaped scanning capillary-tube viscometer ($BVD-PRO1^{(R)}$) which is capable of measuring yield stress and viscosity of whole blood continuously over a wide range of shear rates from $1s^{-1}$ to $1000s^{-1}$ is new type of capillary tube viscometer and calculates viscosity using Casson fluid model. Measured values of WBV, Complete blood cell count, serum chemistry were analyzed by RM-ANOVA test. Mean diastolic and systolic WBV (cP) were $29.032{\pm}6.137$ and $4.528{\pm}0.865$. Bodyweight (BW), Red blood cell count (RBC), Hemoglobin (HGB), Hematocrit (HCT), Alkaline phosphatase (ALP), Cholestetol (CHOL), Total protein (TP), Globulin, Chloride (Cl), Fibrinogen, were statistically correlated with WBV over whole range of shear rates (p < 0.05). This study newly evaluated reference values of WBV by U-shaped viscometer in beagle. Correlation between WBV and BW, RBC, HGB, HCT, ALP, CHOL, TP, Globulin, Cl, Fibrinogen was presented.

• Journal of Ginseng Research
• /
• v.43 no.4
• /
• pp.562-571
• /
• 2019

Background: Ginsenosides have been widely used clinically for many years and were regarded as very safe. However, a few researches on the toxicities of these kinds of agents showed that some ginsenosides may have side-effect on the rats or dogs. So it is extremely necessary to further clarify the potential toxicity of ginsenosides. This study was carried out to investigate long-term toxicity and genotoxicity of 25-methoxydammarane-3, 12, 20-triol ($25-OCH_3-PPD$), a new derivative of ginsenoside, in beagle dogs. Methods: Twenty-four beagle dogs were divided randomly into four treatment groups and repeatedly orally administered with $25-OCH_3-PPD$ capsule at 60, 120, and 240 mg/kg/day for 91 consecutive days. Ames, micronucleus, and chromosomal aberration tests were established to analyze the possible genotoxicity of $25-OCH_3-PPD$. Results: There was no $25-OCH_3-PPD$einduced systemic toxicity in beagle dogs at any doses. The level of $25-OCH_3-PPD$ at which no adverse effects were observed was found to be 240 mg/kg/day. The result of Ames test showed that there was no significant increase in the number of revertant colonies of $25-OCH_3-PPD$ administrated groups compared to the vehicle control group. There were also no significant differences between $25-OCH_3-PPD$ administrated groups at all dose levels and negative group in the micronucleus test and chromosomal aberration assay. Conclusion: The highest dose level of $25-OCH_3-PPD$ at which no adverse effects were observed was found to be 240 mg/kg per day, and it is not a genotoxic agent either in somatic cells or germs cells. $25-OCH_3-PPD$ is an extremely safe candidate compound for antitumor treatment.

• Journal of Pharmaceutical Investigation
• /
• v.29 no.1
• /
• pp.7-12
• /
• 1999

The captopril matrix tablets composed of polyethylene oxide(PEO) was prepared and administered to beagle dogs. Captopril matrix tablets were prepared using direct compressed method and wet granulation compressed method with various ratios of drug to PEO. The diffusion rate of captopril matrix tablets followed on the Higuchi's diffusion model. With increasing hardness of captopril matrix tablets, release rate was decreased. Each formulation was evaluated by the area under the curve (AUC) and time course of plasma captopril concentration after oral administration to beagle dogs. The $AUC_{0-12}$ were $9.126\;{\mu}g\;h/ml$ and $6.417\;{\mu}g\;h/ml$ for the matrix tablets and conventional tablets, respectively. Therefore, the bioavailability of captopril matrix tablets was greater than that of commercial product. It is suggested that captopril matrix tablets using PEO is a useful sustained release formulation.

• Toxicological Research
• /
• v.13 no.3
• /
• pp.293-296
• /
• 1997

The acute toxicity study of CJ-50001, a recombinant granulocyte-colony stimulating factor (rG-CSF), was performed in Sprague Dawley (SD) rats and beagle dogs. CJ-50001 was administered up to maximum dose 5,000 $\mu\textrm{g}$/kg (i.v.) and 10,000 $\mu\textrm{g}$/kg (p.o.) in SD rats and 5,000 $\mu\textrm{g}$/kg (i.v.) in beagle dogs. In these experiments, there were no death and harmful clinical changes which were related to CJ-50001. In conclusion, $LD_{50}$ of CJ-50001 is over 5,000 $\mu\textrm{g}$/kg, i.v. in SD rats and beagle dogs, and over 10,000 $\mu\textrm{g}$/kg, p.o. in SD rats.

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2001.10a
• /
• pp.173-173
• /
• 2001

The acute toxicity study of MBRI-98304, a new Hepatitis B virus (HBV) immunotherapeutic agent, was performed in Sprague-Dawley rats (7 weeks old) and Beagle dogs (4 months old). MBRI-98304 was injected intramuscularly at a single dosage of 0, 20, 100, 500, 2, 500, and 12, 500 $\mu\textrm{g}$/kg in rats and 0, 200, 1, 000, and 5, 000 $\mu\textrm{g}$/kg in Beagle dogs for 2 weeks daily. There were no deaths or clinical signs.(omitted)

• Journal of Life Science
• /
• v.18 no.1
• /
• pp.91-95
• /
• 2008

In human, sympathetic nerve blocks with local anesthetics are widely used to treat a variety of diseases in the innervating regions. However, its procedure in dogs is difficult to approach and process repeatedly because of anatomically location. Therefore, this study was designed to develop a new technique of sympathetic nerve block in beagle dogs. Fifteen healthy beagle dogs, which did not show any neurologic abnormalities and disease, were used for the study. Radiograghs were taken after injected radiopaque material mixed with 2% lidocaine at the cranial cervical ganglion and injected methylene blue using the same percutaneous technique to verify the reliability of this newly developed technique. The successful block rate of the cranial cervical ganglion block was present in 80% of all dogs and the stained cranial cervical ganglions were shown in all dogs. The results show that this new technique of the cranial cervical ganglion block is a reliable and simple method that can be used for clinical studies in dogs.

• Journal of Korean Medicine Rehabilitation
• /
• v.25 no.3
• /
• pp.1-9
• /
• 2015

Objectives To evaluate Shinbaro Pharmacopuncture safety through analysis of potential single-dose intramuscular toxicity of Sinbaro Pharmacopucture in SD rats and Beagle dogs. Methods Single-dose intramuscular toxicity of Shinbaro Pharmacopuncture was assessed in accordance with Korea Food and Drug Administration Guidelines for toxicity testing of Medicinal Products. The SD rats were treated intramuscularly with Shinbaro Pharmacopuncture at doses of 0, 4.6, 9.2, and 18.5 mg/kg, respectively. The Beagle dogs were treated intramuscularly with Shinbaro Pharmacopuncture at doses of 2.3, and 4.6 mg/kg, respectively, and after 3 days, the procedure was repeated a second time at doses of 0.6, and 1.2 mg/kg, respectively, for toxicity testing. Mortality, change in body weight, and necropsy findings were examined for the study period. Results There were no mortalities, general symptoms, or body weight changes in the SD rats. While pyelectasis of the left kidney was observed in a male rat in the 4.6 mg/kg administration group, natural occurrence is common, and does not appear to be related with the test substance. No mortalities were observed in the Beagle dogs. In assessment of general symptoms, a female dog in the 9.2 mg/kg group displayed body weight decrease due to leftover food, but the change in body weight was within the normal range seen at 6~7 months, and the necropsy findings were not significant. The toxicity of the test substance appears to be minimal. Conclusions The results suggest that the lethal dose 50 ($LD_{50}$) and approximate lethaldose (ALD) value in single intramuscular administration of Shinbaro Pharmacopuncture in SD rats and Beagle dogs are higher than 18.5 mg/kg.

• Proceedings of the Korean Society of Veterinary Clinics Conference
• /
• 2006.05a
• /
• pp.210-210
• /
• 2006